Micronised dry powder products | Whole-body dose mg·kg−1 | Exposed dose in the airways µg·kg−1 | Estimated dose of CsA in the airways µg·kg−1 |
CsA# | 26.5±0.4 | 1325.5±21.7 | 1325.5±21.7 |
CsA/G2‐α‐CD¶ | 6.2±0.1 | 309.7±4.6 | 153.9±2.3+ |
G2‐α‐CD¶ | 6.7±0.04 | 334.6±2.2 |
Data are presented as mean±sem
The conditions used in the three different experiments shown in tables 4, 5 and 6⇓⇓⇓ are summarised in this table
#: micronised dry powder of CsA was inhaled by the mice for 60 min at the mean concentration in the chamber of 0.307 mg·L−1
¶: micronised dry powder of CsA/G2‐α‐CD complex and G2‐α‐CD were inhaled by the mice for 10 min at the mean concentration in the chamber of 0.540 mg·L−1 and 0.550 mg·L−1, respectively
+: CsA/G2‐α‐CD complex contains 49.7% (w/w) CsA